IPO
IPO
Best Performers
Forthcoming Issues
Closed Issues
New Listings
Current Issues
IPO Performance
IPO News
IPO Analysis
Basis of Allotment
Draft Prospectus
  HOME  >  IPO  >   IPO SNAPSHOT
IPO Snapshot    
Rubicon Research Ltd.
Issue Open Date 09-Oct-25  
Issue Closing Date 13-Oct-25  
Application Money 100  
Allotment Money  
Price Band 461 - 485  
Minimium Application No. 30  
Issue Size (Shares) 16455670  
Market Lot 1.00  
Objective
1. Prepayment or scheduled repayment of all or a portion of certain outstanding borrowings availed by our Company2. Funding inorganic growth through unidentified acquisitions and other strategic initiatives and General corporate purposes
Category No. of Shares No. of Shares Subscription Ratio
  Offered / Reserved Bid For  
Non-Institutional Investors   4476409   436939170   97.61  
Qualified Institutional Buyers   8952820   1166167740   130.26  
Retail Individual Investors   2984273   105865470   35.47  
Business Description
We are a pharmaceutical formulations company, driven by innovation through focused research and development, with an increasing portfolio of specialty products and drug-device combination products targeting regulated markets and in particular the United States
more...
Promoter's Holding
Total Share Capital   120407506  
Offered to Public   16455670  
Promoter's Holding (Pre-Issue)   77.97  
Promoter's Holding (Post-Issue)   59.99  
Address
Medone House
B-75
Road No. 33
Wagle Estate
Thane (West)
Thane ,
Maharashtra ,
400604
Phone: 022- 61414000
Email: secretarial@rubicon.co.in
Website: www.rubicon.co.in
Registrar
MUFG Intime India Pvt Ltd.
C 101
247 Park
LBS Marg
Vikhroli (West)
Mumbai
Listed at
BSE, NSE
Lead Manager
Axis Capital Ltd.
IIFL Securities Ltd.
JM Financial Ltd.
SBI Capital Markets Ltd
Promoters
General Atlantic Singapore RR Pte. Ltd.
Parag Suganchand Sancheti
Pratibha Pilgaonkar
Sudhir Dhirendra Pilgaonkar
Sumant Sudhir Pilgaonkar
Surabhi Parag Sancheti
Back Back TopTop
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.